Evidence-Based Management of Adverse Events From Cancer Immunotherapy

In this downloadable slideset, review expert insights and recommendations from NCCN Guidelines on identification and management of immune-related adverse events associated with immune checkpoint inhibitor therapy.
John Thompson Headshot
John A. Thompson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.73 MB
Released: May 7, 2019


Provided by the Annenberg Center for Health Sciences at Eisenhower

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Related Content

Interactive online tool with strategies to assess and manage AEs associated with oral targeted therapy for HR+, HER2– breast cancer, from Clinical Care Options

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Dr. Lydia Scarfò on clinical implications of low COVID-19 vaccine efficacy in chronic lymphocytic leukemia (CLL), from Clinical Care Options (CCO)

Lydia Scarfò, MD Released: August 27, 2021

PDF resource for patients and caregivers on the side effects of BTK inhibitor therapy, from Clinical Care Options (CCO)

Anthony Perissinotti, PharmD, BCOP Released: August 25, 2021

Download this short slideset from Clinical Care Options (CCO) on managed care and specialty pharmacy considerations with CAR T-cell therapy

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.